Literature DB >> 26972510

Influence of recombination on acquisition and reversion of immune escape and compensatory mutations in HIV-1.

Pradeep Nagaraja1, Helen K Alexander2, Sebastian Bonhoeffer3, Narendra M Dixit4.   

Abstract

Following transmission, HIV-1 adapts in the new host by acquiring mutations that allow it to escape from the host immune response at multiple epitopes. It also reverts mutations associated with epitopes targeted in the transmitting host but not in the new host. Moreover, escape mutations are often associated with additional compensatory mutations that partially recover fitness costs. It is unclear whether recombination expedites this process of multi-locus adaptation. To elucidate the role of recombination, we constructed a detailed population dynamics model that integrates viral dynamics, host immune response at multiple epitopes through cytotoxic T lymphocytes, and viral evolution driven by mutation, recombination, and selection. Using this model, we compute the expected waiting time until the emergence of the strain that has gained escape and compensatory mutations against the new host's immune response, and reverted these mutations at epitopes no longer targeted. We find that depending on the underlying fitness landscape, shaped by both costs and benefits of mutations, adaptation proceeds via distinct dominant pathways with different effects of recombination, in particular distinguishing escape and reversion. When adaptation at a single epitope is involved, recombination can substantially accelerate immune escape but minimally affects reversion. When multiple epitopes are involved, recombination can accelerate or inhibit adaptation depending on the fitness landscape. Specifically, recombination tends to delay adaptation when a purely uphill fitness landscape is accessible at each epitope, and accelerate it when a fitness valley is associated with each epitope. Our study points to the importance of recombination in shaping the adaptation of HIV-1 following its transmission to new hosts, a process central to T cell-based vaccine strategies.
Copyright © 2015 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cytotoxic T lymphocytes; Fitness landscape; Immune escape; Multi-locus adaptation; Waiting time

Mesh:

Year:  2015        PMID: 26972510     DOI: 10.1016/j.epidem.2015.09.001

Source DB:  PubMed          Journal:  Epidemics        ISSN: 1878-0067            Impact factor:   4.396


  6 in total

Review 1.  Towards multiscale modeling of the CD8+ T cell response to viral infections.

Authors:  Subhasish Baral; Rubesh Raja; Pramita Sen; Narendra M Dixit
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2019-02-27

Review 2.  Nonthermal plasma as part of a novel strategy for vaccination.

Authors:  Hager Mohamed; Rita A Esposito; Michele A Kutzler; Brian Wigdahl; Fred C Krebs; Vandana Miller
Journal:  Plasma Process Polym       Date:  2020-07-13       Impact factor: 3.877

3.  Pre-existing resistance in the latent reservoir can compromise VRC01 therapy during chronic HIV-1 infection.

Authors:  Ananya Saha; Narendra M Dixit
Journal:  PLoS Comput Biol       Date:  2020-11-30       Impact factor: 4.475

4.  Molecular epidemiology and clinical characterization of human rhinoviruses circulating in Shanghai, 2012-2020.

Authors:  Haixia Jiang; Tianyun Yang; Chunyi Yang; Yanping Lu; Zhigang Yi; Qin Zhang; Wei Wang
Journal:  Arch Virol       Date:  2022-03-18       Impact factor: 2.685

5.  Trends of Transmitted and Acquired Drug Resistance in Europe From 1981 to 2019: A Comparison Between the Populations of Late Presenters and Non-late Presenters.

Authors:  Mafalda N S Miranda; Marta Pingarilho; Victor Pimentel; Maria do Rosário O Martins; Rolf Kaiser; Carole Seguin-Devaux; Roger Paredes; Maurizio Zazzi; Francesca Incardona; Ana B Abecasis
Journal:  Front Microbiol       Date:  2022-04-13       Impact factor: 5.640

6.  Transmitted HIV-1 is more virulent in heterosexual individuals than men-who-have-sex-with-men.

Authors:  Ananthu James; Narendra M Dixit
Journal:  PLoS Pathog       Date:  2022-03-10       Impact factor: 6.823

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.